You are here

P&T News

May 26

“Immutable” changes are on the way, regardless of government policies
Causes include growing population of older adults
First biosimilar erythropoiesis-stimulating agent backed by an FDA panel
Finger of suspicion points to Ocrevus, but Tysabri may be the real culprit

May 25

Proposed legislation trims $119 billion from federal deficit
Potentially harmful bacteria acquire antibiotic-resistance genes
Company plans FDA submission by mid-year

May 24

Approval marks major step in precision medicine
Two-year study shows 2.8% improvement in disease-free survival versus placebo
STAT article lists eight ways proposed cuts might affect public health

May 23

California takes steps to reduce overly aggressive care
Centers postpone operations, delay chemotherapy
Wholesale acquisition cost is $39,000 per year

Pages